Download PDF
Semin Thromb Hemost 2021; 47(07): 800-814
DOI: 10.1055/s-0041-1726096
Review Article

Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives

Mikael Christiansen
1   Department of Clinical Biochemistry, Regional Hospital in Horsens, Horsens, Denmark
,
Erik Lerkevang Grove
2   Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
,
Anne-Mette Hvas
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
4   Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The ability of aspirin to inhibit platelet aggregation has positioned this agent within the most frequently used drugs worldwide. The aim of this article is to review the contemporary clinical use of aspirin and also to discuss unresolved issues not yet translated into clinical practice. Results from several clinical trials have led to strong guideline recommendations for aspirin use in the acute management and secondary prevention of cardiovascular disease. On the contrary, guidelines regarding aspirin use as primary prevention of cardiovascular disease are almost conservative, supported by recent trials reporting that the bleeding risk outweighs the potential benefits in most patients. In pregnancy, aspirin has proved efficient in preventing preeclampsia and small-for-gestational-age births in women at high risk, and is hence widely recommended in clinical guidelines. Despite the vast amount of clinical data on aspirin, several unresolved questions remain. Randomized trials have reported that aspirin reduces the risk of recurrent venous thromboembolism, but the clinical relevance remains limited, because direct oral anticoagulants are more effective. Laboratory studies suggest that a twice-daily dosing regimen or evening intake may lead to more efficient platelet inhibition, and the potential clinical benefit of such strategies is currently being explored in ongoing clinical trials. Enteric-coated formulations of aspirin are frequently used, but it remains unclear if they are safer and as efficient as plain aspirin. In the future, aspirin use after percutaneous coronary interventions might not be mandatory in patients who also need anticoagulant therapy, as several trials support shorter aspirin duration strategies. On the other hand, new treatment indications for aspirin will likely arise, as there is growing evidence that aspirin may reduce the risk of colorectal cancer and other types of cancer.

Keywords

aspirin - cardiovascular disease - pregnancy - venous thromboembolism - cancer


Publication History

Article published online:
15 June 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - a concise summary. Vascul Pharmacol 2019; 113: 1-8
    CrossrefPubMedGoogle Scholar
  • 2 Desborough MJR, Keeling DM. The aspirin story - from willow to wonder drug. Br J Haematol 2017; 177 (05) 674-683
    CrossrefPubMedGoogle Scholar
  • 3 Elwood PC, Cochrane AL, Burr ML. et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974; 1 (5905): 436-440
    CrossrefPubMedGoogle Scholar
  • 4 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
    CrossrefPubMedGoogle Scholar
  • 5 Simes J, Becattini C, Agnelli G. et al; INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014; 130 (13) 1062-1071
    CrossrefPubMedGoogle Scholar
  • 6 Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol 2020; 31 (05) 558-568
    CrossrefPubMedGoogle Scholar
  • 7 Christiansen M, Grove EL, Hvas AM. Primary prevention of cardiovascular events with aspirin: toward more harm than benefit - a systematic review and meta-analysis. Semin Thromb Hemost 2019; 45 (05) 478-489
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Osman M, Farjo PD, Osman K. et al. The dawn of aspirin free strategy after short term dual antiplatelet for percutaneous coronary intervention: meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2020; 49 (02) 184-191
    CrossrefPubMedGoogle Scholar
  • 9 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23 (04) 349-356
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989; 259 (02) 315-324
    CrossrefPubMedGoogle Scholar
  • 11 Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367 (9510): 606-617
    CrossrefPubMedGoogle Scholar
  • 12 Patrono C, Ciabattoni G, Pinca E. et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17 (3-4): 317-327
    CrossrefPubMedGoogle Scholar
  • 13 Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992 (01) 66-70
    CrossrefPubMedGoogle Scholar
  • 14 Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977; 11 (03) 323-344
    CrossrefPubMedGoogle Scholar
  • 15 Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104 (03) 390-398
    CrossrefPubMedGoogle Scholar
  • 16 Patrignani P, Tacconelli S, Piazuelo E. et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost 2014; 12 (08) 1320-1330
    CrossrefPubMedGoogle Scholar
  • 17 Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311 (19) 1206-1211
    CrossrefPubMedGoogle Scholar
  • 18 Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2 (08) 637-643
    CrossrefPubMedGoogle Scholar
  • 19 Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353 (22) 2373-2383
    CrossrefPubMedGoogle Scholar
  • 20 Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3, Suppl): 234S-264S
    CrossrefPubMedGoogle Scholar
  • 21 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61 (02) 314-319
    CrossrefPubMedGoogle Scholar
  • 22 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2 (8607): 349-360
    PubMedGoogle Scholar
  • 23 Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998; 316 (7141): 1337-1343
    CrossrefPubMedGoogle Scholar
  • 24 Baigent C, Blackwell L, Collins R. et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-1860
    CrossrefPubMedGoogle Scholar
  • 25 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
    CrossrefPubMedGoogle Scholar
  • 26 Ibánez B, James S, Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed) 2017; 70 (12) 1082
    Google Scholar
  • 27 O'Gara PT, Kushner FG, Ascheim DD. et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127 (04) e362-e425
    PubMedGoogle Scholar
  • 28 Roffi M, Patrono C, Collet JP. et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
    CrossrefPubMedGoogle Scholar
  • 29 Amsterdam EA, Wenger NK, Brindis RG. et al; ACC/AHA Task Force Members, Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130 (25) 2354-2394
    CrossrefPubMedGoogle Scholar
  • 30 Knuuti J, Wijns W, Saraste A. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41 (03) 407-477
    CrossrefPubMedGoogle Scholar
  • 31 Smith Jr SC, Benjamin EJ, Bonow RO. et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124 (22) 2458-2473
    CrossrefPubMedGoogle Scholar
  • 32 Gaziano JM, Brotons C, Coppolecchia R. et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392 (10152): 1036-1046
    CrossrefPubMedGoogle Scholar
  • 33 McNeil JJ, Wolfe R, Woods RL. et al; ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018; 379 (16) 1509-1518
    CrossrefPubMedGoogle Scholar
  • 34 Bowman L, Mafham M, Wallendszus K. et al; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379 (16) 1529-1539
    CrossrefPubMedGoogle Scholar
  • 35 McNeil JJ, Woods RL, Nelson MR. et al; ASPREE Investigator Group. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018; 379 (16) 1499-1508
    CrossrefPubMedGoogle Scholar
  • 36 Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA 2019; 321 (03) 277-287
    CrossrefPubMedGoogle Scholar
  • 37 Gelbenegger G, Postula M, Pecen L. et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med 2019; 17 (01) 198
    CrossrefPubMedGoogle Scholar
  • 38 Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J 2019; 40 (07) 607-617
    CrossrefPubMedGoogle Scholar
  • 39 Sarwar N, Gao P, Seshasai SR. et al; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375 (9733): 2215-2222
    CrossrefPubMedGoogle Scholar
  • 40 Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26 (12) 3264-3272
    CrossrefPubMedGoogle Scholar
  • 41 Belch J, MacCuish A, Campbell I. et al; Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840
    CrossrefPubMedGoogle Scholar
  • 42 Ogawa H, Nakayama M, Morimoto T. et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300 (18) 2134-2141
    CrossrefPubMedGoogle Scholar
  • 43 Schrör K, Kristensen SD, Storey RF, Verheugt FWA. Aspirin and primary prevention in patients with diabetes - a critical evaluation of available randomized trials and meta-analyses. Thromb Haemost 2019; 119 (10) 1573-1582
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Raber I, McCarthy CP, Vaduganathan M. et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 2019; 393 (10186): 2155-2167
    CrossrefPubMedGoogle Scholar
  • 45 Piepoli MF, Hoes AW, Agewall S. et al; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207-274
    CrossrefPubMedGoogle Scholar
  • 46 Arnett DK, Blumenthal RS, Albert MA. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 74 (10) e177-e232
    CrossrefPubMedGoogle Scholar
  • 47 Fox CS, Golden SH, Anderson C. et al; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research, and the American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2015; 132 (08) 691-718
    CrossrefPubMedGoogle Scholar
  • 48 Say L, Chou D, Gemmill A. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014; 2 (06) e323-e333
    CrossrefPubMedGoogle Scholar
  • 49 Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for prevention of preeclampsia. Drugs 2017; 77 (17) 1819-1831
    CrossrefPubMedGoogle Scholar
  • 50 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369 (9575): 1791-1798
    CrossrefPubMedGoogle Scholar
  • 51 Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; (02) CD004659
    PubMedGoogle Scholar
  • 52 Bujold E, Roberge S, Lacasse Y. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2, Pt 1): 402-414
    CrossrefPubMedGoogle Scholar
  • 53 Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216 (02) 110-120.e6
    CrossrefPubMedGoogle Scholar
  • 54 Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017; 216 (02) 121-128.e2
    CrossrefPubMedGoogle Scholar
  • 55 National Institute for Health and Care Excellence: Clinical Guidelines. Hypertension in Pregnancy: Diagnosis and Management. London, UK: National Institute for Health and Care Excellence; 2019
    Google Scholar
  • 56 ACOG Practice Bulletin No. 202: Gestational hypertension and preeclampsia. Obstet Gynecol 2019; 133 (01) e1-e25
    Google Scholar
  • 57 McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am J Obstet Gynecol 2018; 218 (2S): S855-S868
    CrossrefPubMedGoogle Scholar
  • 58 Hoffman MK, Goudar SS, Kodkany BS. et al; ASPIRIN Study Group. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet 2020; 395 (10220): 285-293
    CrossrefPubMedGoogle Scholar
  • 59 Münster AM, Rasmussen TB, Falstie-Jensen AM. et al. A changing landscape: temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006-2015. Thromb Res 2019; 176: 46-53
    CrossrefPubMedGoogle Scholar
  • 60 Prandoni P, Lensing AW, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 61 Becattini C, Agnelli G, Schenone A. et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
    CrossrefPubMedGoogle Scholar
  • 62 Brighton TA, Eikelboom JW, Mann K. et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 (21) 1979-1987
    CrossrefPubMedGoogle Scholar
  • 63 Sobieraj DM, Coleman CI, Pasupuleti V, Deshpande A, Kaw R, Hernandez AV. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thromb Res 2015; 135 (05) 888-896
    CrossrefPubMedGoogle Scholar
  • 64 Weitz JI, Lensing AWA, Prins MH. et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedGoogle Scholar
  • 65 Paven E, Dillinger JG, Bal Dit Sollier C. et al. Determinants of aspirin resistance in patients with type 2 diabetes. Diabetes Metab 2020; 46 (05) 370-376
    CrossrefPubMedGoogle Scholar
  • 66 Larsen SB, Grove EL, Neergaard-Petersen S, Würtz M, Hvas AM, Kristensen SD. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One 2015; 10 (05) e0126767
    CrossrefPubMedGoogle Scholar
  • 67 Zimmermann N, Wenk A, Kim U. et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108 (05) 542-547
    CrossrefPubMedGoogle Scholar
  • 68 Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167 (15) 1593-1599
    CrossrefPubMedGoogle Scholar
  • 69 Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637): 195-198
    CrossrefPubMedGoogle Scholar
  • 70 Hennekens CH, Schneider WR, Hebert PR, Tantry US, Gurbel PA. Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to “aspirin resistance”. Am Heart J 2010; 159 (05) 744-748
    CrossrefPubMedGoogle Scholar
  • 71 Dawson J, Quinn T, Rafferty M. et al. Aspirin resistance and compliance with therapy. Cardiovasc Ther 2011; 29 (05) 301-307
    CrossrefPubMedGoogle Scholar
  • 72 Cuisset T, Frere C, Quilici J. et al. Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting. Am Heart J 2009; 157 (05) 889-893
    CrossrefPubMedGoogle Scholar
  • 73 von Pape KW, Strupp G, Bonzel T, Bohner J. Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. Thromb Haemost 2005; 94 (04) 889-891
    CrossrefPubMedGoogle Scholar
  • 74 Würtz M, Hvas AM, Jensen LO. et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol 2014; 175 (02) 274-279
    CrossrefPubMedGoogle Scholar
  • 75 Henry P, Vermillet A, Boval B. et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105 (02) 336-344
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Christensen KH, Grove EL, Würtz M, Kristensen SD, Hvas AM. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets 2015; 26 (03) 230-235
    CrossrefPubMedGoogle Scholar
  • 77 Guthikonda S, Alviar CL, Vaduganathan M. et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52 (09) 743-749
    CrossrefPubMedGoogle Scholar
  • 78 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99 (05) 930-935
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Larsen ML, Pedersen OH, Hvas AM. et al. Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. Platelets 2019; 30 (03) 322-328
    CrossrefPubMedGoogle Scholar
  • 80 Würtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010; 96 (05) 368-371
    CrossrefPubMedGoogle Scholar
  • 81 Charlot M, Grove EL, Hansen PR. et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690
    CrossrefPubMedGoogle Scholar
  • 82 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345 (25) 1809-1817
    CrossrefPubMedGoogle Scholar
  • 83 Capone ML, Sciulli MG, Tacconelli S. et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45 (08) 1295-1301
    CrossrefPubMedGoogle Scholar
  • 84 Agewall S, Cattaneo M, Collet JP. et al; ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013; 34 (23) 1708-1713 , 1713a–1713b
    CrossrefPubMedGoogle Scholar
  • 85 Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46 (06) 986-993
    CrossrefPubMedGoogle Scholar
  • 86 Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28 (14) 1702-1708
    CrossrefPubMedGoogle Scholar
  • 87 Grove EL, Hvas AM, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103 (06) 1245-1253
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153 (02) 175-181
    CrossrefPubMedGoogle Scholar
  • 89 Grinstein J, Cannon CP. Aspirin resistance: current status and role of tailored therapy. Clin Cardiol 2012; 35 (11) 673-681
    CrossrefPubMedGoogle Scholar
  • 90 Grove EL, Storey RF, Kristensen SD. Can we improve the efficacy of low-dose aspirin?. Thromb Haemost 2014; 112 (06) 1077-1078
    Article in Thieme ConnectPubMedGoogle Scholar
  • 91 Dillinger JG, Drissa A, Sideris G. et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J 2012; 164 (04) 600-606.e1
    CrossrefPubMedGoogle Scholar
  • 92 Capodanno D, Patel A, Dharmashankar K. et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 4 (02) 180-187
    CrossrefPubMedGoogle Scholar
  • 93 Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 2011; 106 (03) 491-499
    Article in Thieme ConnectPubMedGoogle Scholar
  • 94 Bethel MA, Harrison P, Sourij H. et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. Diabet Med 2016; 33 (02) 224-230
    CrossrefPubMedGoogle Scholar
  • 95 Paikin JS, Hirsh J, Ginsberg JS. et al. Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. J Thromb Haemost 2015; 13 (03) 448-456
    CrossrefPubMedGoogle Scholar
  • 96 Paikin JS, Hirsh J, Ginsberg JS. et al. Once versus twice daily aspirin after coronary bypass surgery: a randomized trial. J Thromb Haemost 2017; 15 (05) 889-896
    CrossrefPubMedGoogle Scholar
  • 97 Dillinger JG, Sideris G, Henry P, Bal dit Sollier C, Ronez E, Drouet L. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res 2012; 129 (01) 91-94
    CrossrefPubMedGoogle Scholar
  • 98 Pascale S, Petrucci G, Dragani A. et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119 (15) 3595-3603
    CrossrefPubMedGoogle Scholar
  • 99 Mogabgab O, Wiviott SD, Antman EM. et al. Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol 2013; 36 (04) 222-227
    CrossrefPubMedGoogle Scholar
  • 100 Elliot WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens 2001; 14 (9, Pt 2): 291S-295S
    CrossrefPubMedGoogle Scholar
  • 101 Buurma M, van Diemen JJK, Thijs A, Numans ME, Bonten TN. Circadian rhythm of cardiovascular disease: the potential of chronotherapy with aspirin. Front Cardiovasc Med 2019; 6: 84
    CrossrefPubMedGoogle Scholar
  • 102 Tofler GH, Brezinski D, Schafer AI. et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316 (24) 1514-1518
    CrossrefPubMedGoogle Scholar
  • 103 Bonten TN, Saris A, van Oostrom MJ. et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost 2014; 112 (06) 1209-1218
    Article in Thieme ConnectPubMedGoogle Scholar
  • 104 Racca C, van Diemen JJK, Fuijkschot WW. et al. Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum Thromboxane B2, during infarct-prone early-morning hours. Platelets 2019; 30 (07) 871-877
    CrossrefPubMedGoogle Scholar
  • 105 Bonten TN, Snoep JD, Assendelft WJ. et al. Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial. Hypertension 2015; 65 (04) 743-750
    CrossrefPubMedGoogle Scholar
  • 106 Krasińska B, Paluszkiewicz L, Miciak-Lawicka E. et al. The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: a randomized, controlled trial. Cardiol J 2019; 26 (06) 727-735
    CrossrefPubMedGoogle Scholar
  • 107 van Diemen JJ, Fuijkschot WW, Wessels TJ, Veen G, Smulders YM, Thijs A. Evening intake of aspirin is associated with a more stable 24-h platelet inhibition compared to morning intake: a study in chronic aspirin users. Platelets 2016; 27 (04) 351-356
    CrossrefPubMedGoogle Scholar
  • 108 Lanza FL, Royer Jr GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 303 (03) 136-138
    CrossrefPubMedGoogle Scholar
  • 109 Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32 (01) 77-83
    CrossrefPubMedGoogle Scholar
  • 110 Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther 1999; 13 (08) 1109-1114
    CrossrefPubMedGoogle Scholar
  • 111 Cole AT, Hudson N, Liew LC, Murray FE, Hawkey CJ, Heptinstall S. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?. Aliment Pharmacol Ther 1999; 13 (02) 187-193
    CrossrefPubMedGoogle Scholar
  • 112 Blondon H, Barbier JP, Mahé I, Deverly A, Kolsky H, Bergmann JF. Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formulation versus regular formulation in healthy volunteers. Fundam Clin Pharmacol 2000; 14 (02) 155-157
    CrossrefPubMedGoogle Scholar
  • 113 Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 2011; 106 (02) 272-277
    CrossrefPubMedGoogle Scholar
  • 114 Endo H, Sakai E, Higurashi T. et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44 (10) 833-838
    CrossrefPubMedGoogle Scholar
  • 115 Sørensen HT, Mellemkjaer L, Blot WJ. et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95 (09) 2218-2224
    CrossrefPubMedGoogle Scholar
  • 116 Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348 (9039): 1413-1416
    CrossrefPubMedGoogle Scholar
  • 117 Ridker PM, Hennekens CH, Tofler GH, Lipinska I, Buring JE. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk 1996; 3 (02) 209-212
    CrossrefPubMedGoogle Scholar
  • 118 Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006; 151 (05) 976.e7-976.e11
    CrossrefPubMedGoogle Scholar
  • 119 Coleman JL, Alberts MJ. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Am J Cardiol 2006; 98 (06) 838-841
    CrossrefPubMedGoogle Scholar
  • 120 Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013; 127 (03) 377-385
    CrossrefPubMedGoogle Scholar
  • 121 Bhatt DL, Grosser T, Dong JF. et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2017; 69 (06) 603-612
    CrossrefPubMedGoogle Scholar
  • 122 Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37 (08) 2153-2158
    CrossrefPubMedGoogle Scholar
  • 123 Peace A, McCall M, Tedesco T. et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010; 8 (10) 2323-2325
    CrossrefPubMedGoogle Scholar
  • 124 Maree AO, Curtin RJ, Dooley M. et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46 (07) 1258-1263
    CrossrefPubMedGoogle Scholar
  • 125 Valgimigli M, Bueno H, Byrne RA. et al; ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
    CrossrefPubMedGoogle Scholar
  • 126 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016; 134 (10) e123-e155
    CrossrefPubMedGoogle Scholar
  • 127 Larsen ML, Grove EL, Kristensen SD, Hvas AM. Benefits and harm of treatment with P2Y12 inhibitors beyond 12 months in patients with coronary artery disease. Semin Thromb Hemost 2020; 46 (04) 446-456
    Article in Thieme ConnectPubMedGoogle Scholar
  • 128 Sørensen R, Hansen ML, Abildstrom SZ. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374 (9706): 1967-1974
    CrossrefPubMedGoogle Scholar
  • 129 Pareek M, Bhatt DL, Ten Berg JM, Kristensen SD, Grove EL. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. Expert Opin Pharmacother 2017; 18 (09) 875-883
    CrossrefPubMedGoogle Scholar
  • 130 Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016; 16 (03) 173-186
    CrossrefPubMedGoogle Scholar
  • 131 Mitrugno A, Sylman JL, Ngo AT. et al. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. Am J Physiol Cell Physiol 2017; 312 (02) C176-C189
    CrossrefPubMedGoogle Scholar
  • 132 Patrignani P, Patrono C. Aspirin, platelet inhibition and cancer prevention. Platelets 2018; 29 (08) 779-785
    CrossrefPubMedGoogle Scholar
  • 133 Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13 (05) 518-527
    CrossrefPubMedGoogle Scholar
  • 134 Chan AT, Arber N, Burn J. et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 2012; 5 (02) 164-178
    CrossrefPubMedGoogle Scholar
  • 135 Burn J, Gerdes AM, Macrae F. et al; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378 (9809): 2081-2087
    CrossrefPubMedGoogle Scholar
  • 136 Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159 (02) 77-85
    CrossrefPubMedGoogle Scholar
  • 137 Rothwell PM, Wilson M, Elwin CE. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376 (9754): 1741-1750
    CrossrefPubMedGoogle Scholar
  • 138 Baron JA, Cole BF, Sandler RS. et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348 (10) 891-899
    CrossrefPubMedGoogle Scholar
  • 139 Sandler RS, Halabi S, Baron JA. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348 (10) 883-890
    CrossrefPubMedGoogle Scholar
  • 140 Benamouzig R, Deyra J, Martin A. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125 (02) 328-336
    CrossrefPubMedGoogle Scholar
  • 141 Chan AT, McNeil J. Aspirin and cancer prevention in the elderly: Where do we go from here?. Gastroenterology 2019; 156 (03) 534-538
    CrossrefPubMedGoogle Scholar
  • 142 Bibbins-Domingo K. U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016; 164 (12) 836-845
    CrossrefPubMedGoogle Scholar
  • 143 Qiao Y, Yang T, Gan Y. et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer 2018; 18 (01) 288
    CrossrefPubMedGoogle Scholar
  • 144 Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med 2020; 382 (11) 1018-1028
    CrossrefPubMedGoogle Scholar
  • 145 Elwood PC, Morgan G, Pickering JE. et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One 2016; 11 (04) e0152402
    CrossrefPubMedGoogle Scholar
  • 146 Ishikawa H, Mutoh M, Suzuki S. et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 2014; 63 (11) 1755-1759
    CrossrefPubMedGoogle Scholar
  • 147 Frouws MA, van Herk-Sukel MPP, Maas HA. et al. The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence. Cancer Treat Rev 2017; 55: 120-127
    CrossrefPubMedGoogle Scholar
  • 148 Miyamoto K, Takashima A, Mizusawa J. et al; Colorectal Cancer Study Group of the Japan Clinical Oncology Group. Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial). Jpn J Clin Oncol 2019; 49 (10) 985-990
    CrossrefPubMedGoogle Scholar